ClinicalTrials.Veeva

Menu

Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19

U

Universidade do Porto

Status

Unknown

Conditions

Rehospitalization
Quality of Life
Morality
Long-term Outcomes
Coronavirus Infection

Treatments

Other: COVID-19 Pneumonia

Study type

Observational

Funder types

Other

Identifiers

NCT04416464
QoL_ICU_COVID

Details and patient eligibility

About

Patients suffering from pneumonia due to SARS-CoV-2 infection, after admission to the Intensive Care Unit (ICU), are susceptible to development of various functional sequelae, increased risk of chronic diseases, increased mortality rates and existence of relevant impacts on their quality of life in the months and years that follow the ICU admission. The present study aims to assess the determinants of health-related quality of life and patient-centered long-term outcomes among patients recovered from SARS-COV-2 pneumonia, after discharge from the ICU, its determinants and predictors, in Portugal. It is a multicenter prospective cohort study of adult patients admitted at the ICU due to proven or suspected SARS-CoV-2 infection, included 90 days after discharge from the ICU. The primary outcome is one-year health-related quality of life assessed by the EQ-5D-3L. The secondary outcomes are all-cause mortality, rehospitalizations, return to work or study, the degree of dependence and functional capacity, symptoms of anxiety, depression and post-traumatic stress, level of physical activity and cognitive, renal and respiratory functions after ICU discharge. Investigators will collect data by means of structured telephone interviews, at a 12 months follow up period.

Enrollment

280 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women aged 18 years and older
  • Admission to the intensive care unit (ICU)
  • Pneumonia due to proven or suspected SARS-CoV-2 infection

Exclusion criteria

  • Refusal to provide consent for the study by the patient or legal guardian
  • ICU length of stay less than 24 hours
  • Absence of telephone contact

Trial design

280 participants in 1 patient group

Pneumonia due to SARS-CoV-2 infection
Description:
Adult hospitalized patients with pneumonia due to proven or suspected SARS-Cov-2 infection.
Treatment:
Other: COVID-19 Pneumonia

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems